Randomized, Blinded, Single-arm Intradermal Injection, Control of Similar Products on the Market, the Safety Pre-evaluation Phase I Clinical Trial of BCG-PPD in Tuberculosis Patients
Latest Information Update: 11 May 2023
At a glance
- Drugs BCG-PPD (Primary)
- Indications Tuberculosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Anhui Zhifei Longcom Biopharmaceutical
- 06 May 2023 Planned End Date changed from 1 Oct 2022 to 1 Aug 2023.
- 06 May 2023 Planned primary completion date changed from 1 Sep 2022 to 1 Jul 2023.
- 27 Jun 2022 Planned number of patients changed from 80 to 60.